NAGE
Niagen Bioscience, Inc.
NASDAQ: NAGE · HEALTHCARE · BIOTECHNOLOGY
$4.76
-1.65% today
Updated 2026-04-29
Market cap
$381.18M
P/E ratio
23.80
P/S ratio
2.95x
EPS (TTM)
$0.20
Dividend yield
—
52W range
$4 – $15
Volume
1.2M
WallStSmart proprietary scores
45
out of 100
Grade: C
Sell
Investment rating
6.7
Growth
B5.0
Quality
C+7.5
Profitability
B+6.3
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$13.60
+185.71%
12-Month target
$3.62
-23.95%
Intrinsic (DCF)
$6.93
Margin of safety
+26.26%
0 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 28.30% — strong efficiency
+ Free cash flow $523000.00 — positive
+ Revenue growth 16.20% QoQ
+ 26.26% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $72.05M | $83.57M | $99.60M | $129.42M | $129.42M |
| Net income | $-16.54M | $-4.94M | $8.55M | $17.38M | $4.13M |
| EPS | — | — | — | — | $0.20 |
| Free cash flow | $-15.43M | $6.97M | $11.95M | $13.14M | $523000.00 |
| Profit margin | -22.96% | -5.91% | 8.58% | 13.43% | 13.40% |
Peer comparison
Smart narrative
Niagen Bioscience, Inc. trades at $4.76. representing a P/E of 23.80x trailing earnings. Our Smart Value Score of 45/100 indicates the stock is fair. TTM revenue stands at $129.42M. with profit margins at 13.40%. Our DCF model estimates intrinsic value at $6.93.
Frequently asked questions
What is Niagen Bioscience, Inc.'s stock price?
Niagen Bioscience, Inc. (NAGE) trades at $4.76.
Is Niagen Bioscience, Inc. overvalued?
Smart Value Score 45/100 (Grade C, Sell). DCF value $6.93.
What is the price target of Niagen Bioscience, Inc. (NAGE)?
The analyst target price is $13.60, representing +185.7% upside from the current price of $4.76.
What is the intrinsic value of Niagen Bioscience, Inc. (NAGE)?
Based on our DCF model, intrinsic value is $6.93, a +26.3% margin of safety versus $4.76.
What is Niagen Bioscience, Inc.'s revenue?
TTM revenue is $129.42M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.95x
ROE28.30%
Beta2.24
50D MA$4.78
200D MA$7.03
Shares out0.08B
Float0.05B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—